Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.59 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.52 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233223 | 0.88 | SLC6A5 (0.52) | SLC6A5TAOK1TAOK3P2RX7LMNA | |
| SCHEMBL16233159 | 0.87 | SLC6A5 (0.78) | SLC6A5L3MBTL1LMNAHPGD | |
| SCHEMBL5017438 | 0.87 | SLC6A5 (0.78) | SLC6A5TAOK1TAOK3LMNA | |
| SCHEMBL5022176 | 0.86 | SLC6A5 (0.77) | SLC6A5TAOK1TAOK3LMNA | |
| SCHEMBL5017330 | 0.83 | SLC6A5 (0.74) | SLC6A5TAOK1TAOK3LMNA | |
| SCHEMBL16233224 | 0.82 | HCN1 (0.61) | SLC6A5LMNA | |
| SCHEMBL16233240 | 0.81 | PARP10 (0.53) | SLC6A5LMNA | |
| SCHEMBL13293412 | 0.80 | BRD4 (0.56) | SLC6A5TAOK1TAOK3L3MBTL1LMNA | |
| SCHEMBL6013403 | 0.79 | SLC6A5 (0.89) | SLC6A5TAOK1TAOK3L3MBTL1LMNA | |
| SCHEMBL16233249 | 0.79 | SLC6A5 (0.64) | SLC6A5TAOK1TAOK3LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | SLC6A5 1714/4885TAOK1 3998/4885TAOK3 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.